PCN34 COST-EFFECTIVENESS OF ANASTROZOLE OVERTAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER FROM A UK NATIONAL HEALTH SERVICE PERSPECTIVE: THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL

Cost-effectiveness of anastrozole vs tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer: a UK national health service perspective

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(04)90659-3 ◽

2004 ◽

Vol 2 (3) ◽

pp. 72-73

Author(s):

R.E Mansel

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

National Health Service ◽

Health Service ◽

Adjuvant Therapy ◽

Postmenopausal Women ◽

Early Breast Cancer ◽

National Health ◽

CN4 COST-EFFECTIVENESS OF ANASTROZOLE VS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (EBC): A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE

Value in Health ◽

10.1016/s1098-3015(10)62069-4 ◽

2004 ◽

Vol 7 (3) ◽

pp. 221

Author(s):

Benedict Á

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

National Health Service ◽

Health Service ◽

Adjuvant Therapy ◽

Postmenopausal Women ◽

Early Breast Cancer ◽

National Health ◽

Cost-utility analysis of anastrozole vs tamoxifen in postmenopausal women with early breast cancer from a UK national health service perspective: The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.653 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 653-653 ◽

Cited By ~ 2

Author(s):

R. E. Mansel

Keyword(s):

Breast Cancer ◽

National Health Service ◽

Health Service ◽

Postmenopausal Women ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Treatment Analysis ◽

The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective

Heart ◽

10.1136/heartjnl-2013-304598 ◽

2014 ◽

Vol 100 (13) ◽

pp. 1031-1036 ◽

Cited By ~ 26

Author(s):

A Griffiths ◽

N Paracha ◽

A Davies ◽

N Branscombe ◽

M R Cowie ◽

...

Keyword(s):

Heart Failure ◽

Cost Effectiveness ◽

National Health Service ◽

Chronic Heart Failure ◽

Health Service ◽

National Health ◽

The Uk ◽

The Cost ◽

Cost-Effectiveness Analysis of the use of Coblation Technology Versus Mechanical Debridement in Knee Chondroplasty - A UK National Health Service Perspective

Value in Health ◽

10.1016/j.jval.2018.04.1133 ◽

2018 ◽

Vol 21 ◽

pp. S168

Author(s):

A Adeyemi ◽

L Nherera ◽

P Trueman

Keyword(s):

Cost Effectiveness ◽

National Health Service ◽

Health Service ◽

National Health ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Service Perspective ◽

Health Service Perspective

PCN5 COST-UTILITY ANALYSIS OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (EBC): A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE

Value in Health ◽

10.1016/s1098-3015(10)65739-7 ◽

2004 ◽

Vol 7 (6) ◽

pp. 670 ◽

Cited By ~ 1

Author(s):

R Brown ◽

A Benedict ◽

RE Mansel

Keyword(s):

Breast Cancer ◽

National Health Service ◽

Health Service ◽

Adjuvant Therapy ◽

Postmenopausal Women ◽

Early Breast Cancer ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

EE8 COST EFFECTIVENESS OF CAPECITABINE IN COMBINATION WITH OXALIPLATIN (XELOX) COMPARED TO FOLFOX (5-FU, LV, OXALIPLATIN) FOR THE TREATMENT OF METASTATIC CARCINOMA OF THE COLON OR RECTUM (CRC) FROM A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE

Value in Health ◽

10.1016/s1098-3015(10)66192-x ◽

2008 ◽

Vol 11 (6) ◽

pp. A344

Author(s):

DR Millar ◽

P Ducournau ◽

A McDonald

Keyword(s):

Cost Effectiveness ◽

National Health Service ◽

Health Service ◽

National Health ◽

Metastatic Carcinoma ◽

Carcinoma Of The Colon ◽

2135 POSTER Cost-effectiveness (CE) of lapatinib plus capecitabine (L+C) in women with ErbB2+ (HER2+) metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the United Kingdom (UK) National Health Service (NHS) perspective

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)70897-2 ◽

2007 ◽

Vol 5 (4) ◽

pp. 225 ◽

Cited By ~ 1

Author(s):

T.E. Delea ◽

P. Tappenden ◽

O. Sofrygin ◽

J. Karnon ◽

M. Amonkar ◽

...

Keyword(s):

Breast Cancer ◽

United Kingdom ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

National Health Service ◽

Health Service ◽

Metastatic Breast ◽

Prior Therapy ◽

The United Kingdom ◽

THE COST-EFFECTIVENESS OF SOLIFENACIN VS FESOTERODINE, OXYBUTYNIN IMMEDIATE-RELEASE, PROPIVERINE, TOLTERODINE EXTENDED-RELEASE AND TOLTERODINE IMMEDIATE-RELEASE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN THE UK NATIONAL HEALTH SERVICE

BJU International ◽

10.1111/j.1464-410x.2010.09551_1.x ◽

2010 ◽

Vol 106 (4) ◽

pp. 586-586

Author(s):

Juliet L. Warner

Keyword(s):

Cost Effectiveness ◽

National Health Service ◽

Health Service ◽

Overactive Bladder ◽

National Health ◽

Extended Release ◽

Immediate Release ◽

The Uk ◽

The Cost

The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service

BJU International ◽

10.1111/j.1464-410x.2009.09160.x ◽

2010 ◽

Vol 106 (4) ◽

pp. 506-514 ◽

Cited By ~ 37

Author(s):

Linda Cardozo ◽

Andrew Thorpe ◽

Juliet Warner ◽

Manpreet Sidhu

Keyword(s):

Cost Effectiveness ◽

National Health Service ◽

Health Service ◽

Overactive Bladder ◽

National Health ◽

Extended Release ◽

Immediate Release ◽

The Uk ◽

The Cost